OBJECTIVES: This PMPRB study analyzes the coverage of drugs reviewed by the CDR across Canadian public drug plans, and examines both the number of drugs and the extent of reimbursement. METHODS: The drugs reviewed by the CDR from December 2003 through June 2015, along with their listings as of December 2015, were obtained from IMS Brogan’s iMAM and public formularies. The sales data for 2015 was retrieved from the IMS Brogan Private Drug Plan and IMS AG MIDAS™ databases. The coverage rates for 10 provincial drug plans and the NIHB were calculated as simple and weighted percentages of all select drugs. The analysis also includes an inter-jurisdictional comparison using simple agreement descriptive statistics.  RESULTS: The CDR issued positive recommendations for 55% of the analyzed drugs, with provinces following the CDR recommendation in 78% of the cases. With sales weighting, most provinces listed all major drugs. An inter-jurisdictional comparison of all CDR drugs indicates medium to high rates of coverage agreement, ranging from 50% to 86% across all pairs of the public drug plans. When weighted by sales, the percentage of coverage agreements notably increases. CONCLUSIONS: The study results suggest a relatively high coverage and inter-jurisdictional agreement of the CDR drugs, and highlights differences across public drug plans. These findings are expected to inform policy discussions around a national formulary.